#153962

Anti-HPV-16 E2

Cat. #153962

Anti-HPV-16 E2

Cat. #: 153962

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: HPV-16 E2

Class: Polyclonal

Application: IF ; IP ; WB

Reactivity: Human papilloma virus

Host: Rabbit

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lawrence Banks

Institute: International Centre For Genetic Engineering And Biotechnology (ICGEB)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-HPV-16 E2
  • Alternate name: Human papillomavirus type 16 E2 protein
  • Tool sub type: Primary antibody
  • Class: Polyclonal
  • Conjugation: Unconjugated
  • Molecular weight: 43 kDa
  • Reactivity: Human papilloma virus
  • Host: Rabbit
  • Application: IF ; IP ; WB
  • Description: Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. HPV type 16 is the most malignant strain, present in 41 to 54% of all cervical cancers, and in many cases of vaginal/vulvar cancer, penile cancers, anal cancers, and cancers of the head and neck. In 2012, about 528,000 new cases and 266,000 deaths from cervical cancer occurred worldwide. HPV viral genes E6 and E7 acts as oncogenes to promote tumour formation and malignant transformation. The E2 proteins are pivotal to the viral life cycle and have well characterized functions in transcriptional regulation, initiation of DNA replication and partitioning the viral genome. All E2 proteins are sequence specific DNA binding proteins that bind to 12bp motifs located mostly within the Upstream Regulatory Region (URR) of the viral genomes.
  • Immunogen: Recombinant HPV-16 E2

Target Details

  • Target: HPV-16 E2
  • Molecular weight: 43 kDa
  • Target background: Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. HPV type 16 is the most malignant strain, present in 41 to 54% of all cervical cancers, and in many cases of vaginal/vulvar cancer, penile cancers, anal cancers, and cancers of the head and neck. In 2012, about 528,000 new cases and 266,000 deaths from cervical cancer occurred worldwide. HPV viral genes E6 and E7 acts as oncogenes to promote tumour formation and malignant transformation. The E2 proteins are pivotal to the viral life cycle and have well characterized functions in transcriptional regulation, initiation of DNA replication and partitioning the viral genome. All E2 proteins are sequence specific DNA binding proteins that bind to 12bp motifs located mostly within the Upstream Regulatory Region (URR) of the viral genomes.

Applications

  • Application: IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: Serum
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Johansson et al. 2012. EMBO J. 31(14):3212-27. PMID: 22617423.
  • HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation.